CollPlant Biotechnologies Ltd. (CLGN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CLGN
- Company CollPlant Biotechnologies Ltd.
- Price $0.36
- Changes Percentage 23.58
- Change 0.0683
- Day Low $0.26
- Day High $0.41
- Year High $3.18
- Year Low $0.27
- Market Cap $4,050,786
- Price Avg 50 EMA (D) $0.33
- Price Avg 200 EMA (D) $0.87
- Exchange NASDAQ
- Volume 30,635
- Average Volume 60,237
- Open $0.29
- Previous Close $0.29
- EPS -1.04
- PE -0.30
- Earnings Announcement 2026-08-20 12:00:00
- Shares Outstanding $12,966,666
Company brief: COLLPLANT BIOTECHNOLOGIES LTD. (CLGN )
- Healthcare
- Biotechnology
- Mr. Yehiel Tal
- https://www.collplant.com
- IL
- N/A
- 01-31-2018
- IL0004960188
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.